LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

World’s First Rapid Saliva-Based Pregnancy Test Set for Multi-Country Launch

By LabMedica International staff writers
Posted on 09 Nov 2022
Print article
Image: SaliStick is the first pregnancy test that does not require urine (Photo courtesy of Salignostics)
Image: SaliStick is the first pregnancy test that does not require urine (Photo courtesy of Salignostics)

Saliva contains over 5,000 identified proteins. With significant overlap to blood, saliva is considered the second most important body-fluid for diagnostics. Now, the world’s first saliva-based pregnancy test is all set to arrive in stores across Europe, South Africa, United Arab Emirates, and Israel in the first quarter of 2023. By analyzing saliva, the test completely removes the need for blood and urine samples when testing for pregnancy.

Salistick from Salignostics (Jerusalem, Israel) is the first rapid saliva-based pregnancy test with a new and improved user-experience, and high accuracy for early pregnancy detection. The kit is based on the company’s revolutionary technology which opens the door for a sensitive detection of the pregnancy hormone β-hCG in saliva. The simple, easy to use test can be done anywhere, at any time, without the need for a restroom and delivers accurate results in no more than 10 minutes.

Salistick has already been approved by the European CE certification and has received Medical Devices and Accessories approval from Israel’s Ministry of Health. Salignostics has also completed a 510(K) initial Q-submission of SaliStick to the US FDA. In order to support the commercialization of SaliStick, Salignostics has established a new manufacturing facility in Israel with a monthly production capacity of one million units.

Related Links:
Salignostics 

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Unstirred Waterbath
HumAqua 5
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more